People

GSK’s high-level management makeover continues as CEO Emma Walmsley oversees changing of the guard

The big shakeup in the inner executive circle around CEO Emma Walmsley is continuing today, with two top appointments at GlaxoSmithKline — and one key exit.

Regis Simard

Luc Debruyne is out at the end of this year as president of vaccines after a 5-year stint. Roger Connor, who runs global manufacturing and supply, takes that role September 1. Regis Simard is being appointed president, pharmaceutical supply chain, and will join the corporate executive team.

Walmsley has been doing a total overhaul of the top team in the wake of her arrival in the CEO suite. The changeover includes a new R&D chief — Hal Barron — and plenty of new faces from the oncology world as GSK looks to break out of the innovation doldrums.


Image: Roger Connor and Luc Debruyne. GSK


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->